Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 6/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 2/20 | 0.51 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641790 | 0.88 | GRB2 (0.49) | CALCRLAGTR2AGTR1SLC6A2CMA1 | |
| SCHEMBL29641650 | 0.88 | GRB2 (0.49) | CALCRLAGTR2AGTR1SLC6A2CMA1 | |
| SCHEMBL30760717 | 0.87 | REN (0.55) | SLC6A2RENOPRM1OPRD1OPRK1 | |
| SCHEMBL30150546 | 0.86 | GRB2 (0.52) | CALCRLAGTR2AGTR1SLC6A2CMA1 | |
| SCHEMBL30150551 | 0.86 | CALCRL (0.58) | CALCRLAGTR2AGTR1SLC6A2RAMP1 | |
| SCHEMBL29680100 | 0.85 | F2 (0.56) | CALCRLSLC6A2RAMP1OPRM1OPRD1 | |
| SCHEMBL38665437 | 0.85 | CAPN1 (0.54) | CALCRLSLC6A2RENOPRM1OPRD1 | |
| SCHEMBL29695430 | 0.85 | OPRM1 (0.58) | SLC6A2OPRM1OPRD1OPRK1 | |
| SCHEMBL29664244 | 0.83 | OPRM1 (0.57) | OPRM1OPRD1OPRK1 | |
| SCHEMBL29641646 | 0.82 | GRB2 (0.48) | CALCRLAGTR2AGTR1RAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409709-A1 | LABYRINTHIN-BASED PEPTIDES FOR CANCER IMMUNOTHERAPIES AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS USA LTD (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220089719-A1 | CONSTRUCTS TARGETING LABYRINTHIN OR A PORTION THEREOF AND USES THEREOF | LABYRX IMMUNOLOGIC THERAPEUTICS (USA) LIMITED (US) | 2022-03-24 | — | — | US | disclosed |